Table 1 Clinicopathological features for 164 metastatic breast cancer patients
Total patients (n = 164) | FOXA1-positive (n = 86) | FOXA1-negative (n = 52) | P-value | Nestin-positive (n = 26) | Nestin-negative (n = 114) | P-value | |
|---|---|---|---|---|---|---|---|
Age (y) | 0.21 | 0.29 | |||||
≤ 55 | 59 (36%) | 22 (26%) | 20 (38%) | 10 (38%) | 33 (29%) | ||
56–80 | 94 (57%) | 59 (69%) | 28 (33%) | 16 (62%) | 72 (63%) | ||
> 80 | 11 (7%) | 5 (6%) | 4 (5%) | 0 (0%) | 9 (8%) | ||
Metastasic site | 0.31 | 0.06 | |||||
Abdomen/GI tract/Liver | 44 (27%) | 29 (34%) | 9 (17%) | 5 (19%) | 34 (30%) | ||
Axillary lymph node/sentinel node | 11 (7%) | 5 (6%) | 3 (6%) | 1 (4%) | 7 (6%) | ||
Brain | 29 (18%) | 7 (8%) | 9 (17%) | 8 (31%) | 9 (8%) | ||
Cervical lymph nodes | 3 (2%) | 2 (2%) | 1 (2%) | 0 (0%) | 3 (3%) | ||
Gynecological site | 9 (5%) | 2 (2%) | 7 (13%) | 2 (8%) | 7 (6%) | ||
Skeleton | 37 (23%) | 20 (23%) | 15 (29%) | 3 (12%) | 32 (28%) | ||
Skin | 11 (7%) | 7 (8%) | 4 (8%) | 3 (12%) | 8 (7%) | ||
Thorax/Lung | 20 (12%) | 14 (16%) | 4 (8%) | 4 (15%) | 14 (12%) | ||
Not available | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
GATA3 status | 2.80E-04 | 0.039 | |||||
Positive | 154 (94%) | 86 (100%) | 44 (85%) | 22 (85%) | 110 (96%) | ||
Negative | 10 (6%) | 0 (0%) | 8 (15%) | 4 (15%) | 4 (4%) | ||
Not available | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Mammoglobin status | 0.080 | 0.83 | |||||
Positive | 84 (51%) | 47 (55%) | 20 (38%) | 12 (46%) | 57 (50%) | ||
Negative | 80 (49%) | 39 (45%) | 32 (62%) | 14 (54%) | 57 (50%) | ||
Not available | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
FOXA1 status | 0.0039 | ||||||
Positive | 86 (52%) | – | – | 9 (35%) | 77 (68%) | ||
Negative | 52 (32%) | – | – | 17 (65%) | 35 (31%) | ||
Not available | 26 (16%) | – | – | 0 (0%) | 2 (2%) | ||
Nestin status | 0.0017 | ||||||
Positive | 26 (16%) | 9 (10%) | 17 (33%) | – | – | ||
Negative | 114 (70%) | 77 (90%) | 35 (67%) | – | – | ||
Not available | 24 (15%) | 0 (0%) | 0 (0%) | – | – | ||
Primary tumor differentiation | 0.29 | 0.96 | |||||
Well | 10 (6%) | 5 (6%) | 3 (6%) | 1 (4%) | 7 (6%) | ||
Moderate | 49 (30%) | 31 (36%) | 11 (21%) | 7 (27%) | 36 (32%) | ||
Poor | 59 (36%) | 27 (31%) | 19 (37%) | 9 (35%) | 37 (32%) | ||
Not available | 46 (28%) | 23 (27%) | 19 (37%) | 9 (35%) | 34 (30%) | ||
Axillary lymph node status | 0.047 | 1.00 | |||||
pN0 | 55 (34%) | 34 (40%) | 11 (21%) | 9 (35%) | 37 (32%) | ||
pN1 | 78 (48%) | 38 (44%) | 26 (50%) | 12 (46%) | 53 (46%) | ||
Not available | 31 (19%) | 14 (16%) | 15 (29%) | 5 (19%) | 24 (21%) | ||
ER status | 2.09E-05 | 0.024 | |||||
Positive | 115 (70%) | 74 (86%) | 27 (52%) | 14 (54%) | 89 (78%) | ||
Negative | 49 (30%) | 12 (14%) | 25 (48%) | 12 (46%) | 25 (22%) | ||
Not available | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
PR status | 0.07 | 0.50 | |||||
Positive | 57 (35%) | 39 (45%) | 15 (29%) | 8 (31%) | 46 (40%) | ||
Negative | 107 (65%) | 47 (55%) | 37 (71%) | 18 (69%) | 68 (60%) | ||
Not available | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
HER2/neu status | 0.0031 | 0.42 | |||||
Positive | 45 (27%) | 29 (34%) | 6 (12%) | 4 (15%) | 31 (27%) | ||
Negative | 116 (71%) | 55 (64%) | 46 (88%) | 22 (85%) | 81 (71%) | ||
Not available | 3 (2%) | 2 (2%) | 0 (0%) | 0 (0%) | 2 (2%) | ||
Triple negative status | 1.92E-06 | 0.0021 | |||||
Triple negative | 27 (16%) | 4 (5%) | 19 (37%) | 10 (38%) | 13 (11%) | ||
Non-triple negative | 137 (84%) | 82 (95%) | 33 (63%) | 16 (62%) | 101 (89%) | ||
Not available | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Overall survival | 0.17 | 1.00 | |||||
Deceased | 88 (54%) | 68 (79%) | 46 (88%) | 22 (85%) | 94 (82%) | ||
Survivor | 76 (46%) | 18 (21%) | 6 (12%) | 4 (15%) | 20 (18%) |